Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases
about
Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the HeadThe evolution of poxvirus vaccinesMiddle East respiratory syndrome: obstacles and prospects for vaccine developmentVaccines for Epidemic Infections and the Role of CEPIUniversal influenza virus vaccines and therapeutic antibodies.Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.Strategies towards universal pandemic influenza vaccines.Universal influenza vaccines: Shifting to better vaccines.Viral vector-based influenza vaccines.Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 MiceProtective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins.Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus.Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral ChallengeInfluenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineageMosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza VirusesEnhancing titres of therapeutic viral vectors using the transgene repression in vector production (TRiP) system.Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo.Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike GlycoproteinInduction of influenza (H5N8) antibodies by modified vaccinia virus Ankara H5N1 vaccine.Studies on influenza virus transmission between ferrets: the public health risks revisited.Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?Suppression of Poxvirus Replication by Resveratrol.Universal influenza vaccines, science fiction or soon reality?The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice.Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines.Avian Influenza A Virus Pandemic Preparedness and Vaccine DevelopmentInduction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical TrialNanoparticle Vaccines Against Infectious Diseases
P2860
Q26783897-F54CF575-23D4-48AE-8CF3-14606D6E4419Q26995905-6840D5BA-F990-4205-B04F-B93520EDBD2BQ27013314-97BBDDB8-E7E3-4B92-B97D-EB881EE00114Q29224804-9B25B9C3-D2C9-4C17-82FC-9FB998EBFB5AQ30151337-FACC7F80-A92E-445A-9BA8-22226784D721Q30375380-12F3A4E9-8955-4058-8692-83B565AC5586Q30382226-BAE540D4-A00E-4813-B52E-B5E9A607540CQ30386388-F1C7DC9D-D35B-4E1A-9733-833C34897798Q30390938-3502883B-53E1-4132-BBF6-9FD59B0E0CF9Q30392456-FAF7D009-7974-4C8B-80B7-0AF6A7A100DFQ30397362-55FB8C94-0EB2-444D-9788-31856D43B1A7Q30397410-35DBED8B-EAB3-4621-8175-5D7AD4550901Q36104042-BEC8DB34-685D-4DB3-BE26-5452269A2DE9Q36376605-87A09B13-9455-43D0-8BCC-A74023268D00Q37093491-975B04EF-57CF-44FB-8FB6-E0C7D8F78333Q37736299-EFCF8AC8-7102-4D1F-9260-3F3E67F869C2Q38619090-78C632C5-FB2C-48B4-A77B-E62DEAC09F47Q40139850-7EC4FF70-7D5C-4CD7-94F6-B35269103D55Q41199088-60CBBED9-DE59-4EDA-BFE6-425F2D1D8BFBQ42787449-CC3C79DE-DC89-4C0E-8E16-BC934F91600AQ42958790-49E68261-7228-46ED-8F09-BA51B074EFB0Q45325213-C5A5C771-EAE2-4E88-B989-D429ED9A8CCBQ47107948-8941C1CD-2608-4048-8358-35E1EC805D6EQ51003270-9B99B48F-C70F-453B-89DA-B736323BED83Q52573695-8311D31D-2668-45A4-AE06-8A0B7B935096Q52620757-ACDC566B-ABB0-424E-9FF2-AFCA09F653A3Q52623520-5DB5EE40-BB3B-472A-8359-B387EC521747Q55114818-523BEA0F-FECA-42F6-AFD9-2C3777B258E3Q56561344-6045FAC1-5F79-4942-8079-4B48C7D79995Q56562454-E1588849-39E0-412B-9E1B-A2DF0897AEB5Q58583890-4923CF3F-FC73-40E8-BC6E-959D2D462163
P2860
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Modified vaccinia virus ankara ...... her viral respiratory diseases
@ast
Modified vaccinia virus ankara ...... her viral respiratory diseases
@en
type
label
Modified vaccinia virus ankara ...... her viral respiratory diseases
@ast
Modified vaccinia virus ankara ...... her viral respiratory diseases
@en
prefLabel
Modified vaccinia virus ankara ...... her viral respiratory diseases
@ast
Modified vaccinia virus ankara ...... her viral respiratory diseases
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Modified vaccinia virus ankara ...... her viral respiratory diseases
@en
P2093
Arwen F Altenburg
Asisa Volz
Guus F Rimmelzwaan
Joost H C M Kreijtz
P2860
P304
P356
10.3390/V6072735
P5008
P577
2014-07-17T00:00:00Z